Harnessing BMSCs for ischemic stroke: Decoding multimodal repair and navigating the path to clinical translation

IF 4.5 3区医学 Q2 NEUROSCIENCES

Brain Research Bulletin Pub Date : 2026-11-01 Epub Date: 2026-10-17 DOI:10.1016/j.brainresbull.2026.112170

Xinyi Huang, XiaoLing Chen, GuoLiang Zhu, HongWei Deng, YaPeng Lin, JiangMin Li, KeJie Chen, JunLi Hao, QuanDan Tan, Jie Yang

{"title":"Harnessing BMSCs for ischemic stroke: Decoding multimodal repair and navigating the path to clinical translation","authors":"Xinyi Huang, XiaoLing Chen, GuoLiang Zhu, HongWei Deng, YaPeng Lin, JiangMin Li, KeJie Chen, JunLi Hao, QuanDan Tan, Jie Yang","doi":"10.1016/j.brainresbull.2026.112170","DOIUrl":null,"url":null,"abstract":"<div><div>Ischemic stroke (IS) is characterized by a high incidence rate, high disability rate and high recurrence rate. The existing treatment methods have limitations such as a narrow time window and limited recovery of neurological function. Bone marrow mesenchymal stem cells (BMSCs) have become a research hotspot in the regenerative treatment of IS due to their multi-directional differentiation potential, paracrine regulation and immune regulation characteristics. This review explores the mechanism of action, strategies for enhancing therapeutic efficacy and the progress of clinical transformation of BMSCs in the treatment of IS. Basic research indicates that BMSCs improve neurological function through multiple mechanisms such as migrating to ischemic foci, secreting neurotrophic factors, promoting angiogenesis, and inhibiting apoptosis of nerve cells. Gene modification technology and the application of exosomes can further potentiate therapeutic efficacy. The optimization of injection routes, cell types, transplantation time Windows and cell doses is crucial to the therapeutic effect. Clinical studies have initially confirmed the safety of BMSCs treatment and some functional improvement effects, but there are still problems such as small sample size and unclear long-term efficacy. In the future, it is necessary to further clarify the treatment mechanism, optimize the treatment plan, and promote the transformation of basic research into clinical practice (Graphical Abstract).</div></div>","PeriodicalId":9302,"journal":{"name":"Brain Research Bulletin","volume":"246 ","pages":"Article 112170"},"PeriodicalIF":4.5000,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain Research Bulletin","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0361923026004570","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/10/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Ischemic stroke (IS) is characterized by a high incidence rate, high disability rate and high recurrence rate. The existing treatment methods have limitations such as a narrow time window and limited recovery of neurological function. Bone marrow mesenchymal stem cells (BMSCs) have become a research hotspot in the regenerative treatment of IS due to their multi-directional differentiation potential, paracrine regulation and immune regulation characteristics. This review explores the mechanism of action, strategies for enhancing therapeutic efficacy and the progress of clinical transformation of BMSCs in the treatment of IS. Basic research indicates that BMSCs improve neurological function through multiple mechanisms such as migrating to ischemic foci, secreting neurotrophic factors, promoting angiogenesis, and inhibiting apoptosis of nerve cells. Gene modification technology and the application of exosomes can further potentiate therapeutic efficacy. The optimization of injection routes, cell types, transplantation time Windows and cell doses is crucial to the therapeutic effect. Clinical studies have initially confirmed the safety of BMSCs treatment and some functional improvement effects, but there are still problems such as small sample size and unclear long-term efficacy. In the future, it is necessary to further clarify the treatment mechanism, optimize the treatment plan, and promote the transformation of basic research into clinical practice (Graphical Abstract).

查看原文本刊更多论文

利用骨髓间充质干细胞治疗缺血性中风：解码多模态修复并引导临床转化之路。

缺血性脑卒中具有发病率高、致残率高、复发率高的特点。现有的治疗方法存在时间窗窄、神经功能恢复有限等局限性。骨髓间充质干细胞（Bone marrow mesenchymal stem cells, BMSCs）因其多向分化潜能、旁分泌调节和免疫调节等特点，成为IS再生治疗的研究热点。本文就骨髓间充质干细胞治疗IS的作用机制、提高疗效的策略及临床转化研究进展作一综述。基础研究表明，骨髓间充质干细胞通过向缺血病灶迁移、分泌神经营养因子、促进血管生成、抑制神经细胞凋亡等多种机制改善神经功能。基因修饰技术和外泌体的应用可以进一步增强治疗效果。注射途径、细胞类型、移植时间窗和细胞剂量的优化是影响治疗效果的关键。临床研究初步证实了骨髓间充质干细胞治疗的安全性和一定的功能改善效果，但仍存在样本量小、长期疗效不明确等问题。未来需要进一步明确治疗机制，优化治疗方案，推动基础研究向临床实践转化（图示摘要）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Brain Research Bulletin 医学-神经科学

CiteScore

6.90

自引率

2.60%

发文量

253

审稿时长

67 days

期刊介绍： The Brain Research Bulletin (BRB) aims to publish novel work that advances our knowledge of molecular and cellular mechanisms that underlie neural network properties associated with behavior, cognition and other brain functions during neurodevelopment and in the adult. Although clinical research is out of the Journal''s scope, the BRB also aims to publish translation research that provides insight into biological mechanisms and processes associated with neurodegeneration mechanisms, neurological diseases and neuropsychiatric disorders. The Journal is especially interested in research using novel methodologies, such as optogenetics, multielectrode array recordings and life imaging in wild-type and genetically-modified animal models, with the goal to advance our understanding of how neurons, glia and networks function in vivo.